PubMed COVID-19 Clinical Care

CONCLUSION: As part of combination therapy, the bacteria-based immunostimulant agent Immunovac VP4 increases SIgA levels in the nasal and pharyngeal compartments and induces clinical improvement. Induced mucosal immunity is central to the prevention

CONCLUSIONS: This study showed shifting trends of HABP-causing microorganisms in terms of annual incidence accompanied by shifting trends of their resistance rates to major therapeutic antimicrobial agents. HABP-causing bacterial pathogens, their

The current study investigated adolescents' experiences of COVID-19 anti-Chinese discrimination (i.e., vicariously witnessed, directly experienced), the consequences for mental health, and the moderating role of general pandemic stress. During Summer

The COVID-19 infection caused by SARS-CoV-2 is a healthcare crisis that has led to unparalleled disruption and has impacted healthcare services, leading to significant morbidity and mortality in the worldwide population. Insufficient data on the

No abstract

BACKGROUND The COVID-19 pandemic necessitated swift and often abrupt changes in healthcare practices, significantly influencing treatment and diagnostic procedures. This study aimed to gauge patient perceptions regarding these changes and their

CONCLUSION: SARS-CoV-2 infection has been linked to adrenal damage and AI is a rare complication in COVID-19 disease, requiring prompt recognition. Educational efforts and patient awareness may reduce COVID-19 severity in patients with AI. Control of

No abstract

CONCLUSIONS: In preprint articles of COVID-19 treatments, the provided primary outcome is generally reliable, while interpretation of secondary outcomes should be made with caution, while awaiting completion of the peer-review process.

CONCLUSIONS: Immunoglobulin preparations now contain neutralising anti-SARS-CoV-2 antibodies which are transmitted to patients and help to treat COVID-19 in individuals with failure of humoral immunity.